ayala
pharmaceuticals
host
virtual
kol
event
reviewing
interim
data
presented
esmo
ongoing
phase
accuracy
trial
treatment
recurrent
metastatic
adenoid
cystic
carc
rehovot
israel
wilmington
globe
newswire
ayala
pharmaceuticals
nasdaq
ayla
oncology
company
focused
developing
commercializing
small
molecule
therapeutics
patients
suffering
rare
aggressive
cancers
primarily
genetically
defined
patient
populations
today
announced
host
virtual
key
opinion
leader
kol
event
review
new
interim
data
presented
ongoing
phase
accuracy
study
treatment
recurrent
metastatic
r
adenoid
cystic
carcinoma
acc
harbouring
notch
activating
mutations
european
society
medical
oncology
esmo
virtual
congress
event
take
place
friday
september
et
event
feature
presentations
ayala
management
kol
alan
ho
medical
oncologist
memorial
sloan
kettering
cancer
center
lead
investigator
accuracy
trial
live
webcast
event
available
events
presentations
section
ayala
website
access
call
please
dial
united
states
canada
international
reference
conference
id
replay
webcast
accompanying
slides
available
ayala
website
days
following
event
ayala
pharmaceuticals
ayala
pharmaceuticals
oncology
company
focused
developing
commercializing
small
molecule
therapeutics
patients
suffering
rare
aggressive
cancers
primarily
genetically
defined
patient
populations
ayala
approach
focused
predicating
identifying
addressing
tumorigenic
drivers
cancer
combination
bioinformatics
platform
sequencing
deliver
targeted
therapies
underserved
patient
populations
company
two
product
candidates
development
targeting
aberrant
activation
notch
pathway
gamma
secretase
inhibitors
treat
variety
tumors
including
adenoid
cystic
carcinoma
triple
negative
breast
cancer
tnbc
acute
lymphoblastic
leukemia
desmoid
tumors
multiple
myeloma
mm
collaboration
novartis
ayala
lead
product
candidate
received
fast
track
designation
orphan
drug
designation
fda
currently
phase
clinical
trial
patients
acc
accuracy
bearing
notch
activating
mutations
phase
clinical
trial
patients
tnbc
tenacity
bearing
notch
activating
mutations
gene
rearrangements
information
visit
contacts
investors
julie
seidel
stern
investor
relations
